AuraSense Therapeutics is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.
SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. AuraSense Therapeutics' intellectual property portfolio includes over 130 patent applications and 27 allowed or issued patents. These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements. AuraSense Therapeutics is a subsidiary of AuraSense, LLC.
Biotuesdays: In Conversation with David Giljohann
AuraSense Therapeutics Adds to Series C Financing
David Giljohann Named Among Top 40 Under 40 by Analytical Scientist
Google’s Newest Search: Cancer Cells
AuraSense Therapeutics Expands Leadership Team